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I n the last 4 years we have explored the biochemical mechanisms in which glucocorticoids such as prednisone help to mediate a "hair growth" response in patients with alopecia areata (AA). It is well known that steroids are commonly used intralesionally, topically , or orally, to treat 
AA and yet we do not know how glucocorticoids biochemically 
work in the skin to mediate hair growth. Many patients have a 
"variable" response to glucocorticoid treatment. Why some pa­
tients respond to glucocorticoid therapy and others do not has been 
our focus for better understanding the complex biochemical pro­
cesses taking place in AA. 
Fifteen patients with AA totaHs/universalis, with more than 
75% scalp involvement had scalp biopsies pre-glucocorticoid (no 
prior therapy 1 month before biopsy) and post-glucocorticoid 
treatment (oral , intralesional, or topical glucocorticoid therapy 
for 3 months). Scalp biopsies from other patients included 15 
patients with androgenetic alopecia, and 15 normal scalp biop­
sies used as controls. Our studies from 1990 -1 992 National 
Alopecia Areata Foundation awards revealed several important 
findings with regard to glucocorticoid biochemical pathway (Fig 
1): 1) the glucocorticoid receptor (GCR) is elevated and unoc­
cupied in AA patients who are "glucocorticoid resistant" (no 
hair growth response when treated with glucocorticoids); 
2) GCR in these patients are found to be in an "inactive" 
unoccupied state, unable to bind glucocorticoids to the ligand 
binding site of GCR, hence suppressed cellular transcription; 
3) AA patients have low levels of thioredoxin reductase (TR) 
(M = 0.56 2: 0.35 in AA, versus 1.90::':: 0.80 nmoles/mg protein 
in normal controls), an enzyme that "activates" the GCR 
necessary for optimum hormone binding to take place; 4) AA 
patients that were unresponsive (no hair growth) to GC therapy 
had TR levels M = 0.38 2: 0.12, n = 7; versus AA hair growth 
"responsive" patients, n = 8, M = 0.71 ::':: 0.20 nmollmg 
protein, indicating that TR may be depressed but still at a level 
capable of activating GCR to induce hair growth; 5) levels of 
calcium/ calmodulin were found to be altered in these patients, 
which can affect TR levels for GCR "activation" (via sulfhydryl 
reduction) and the phosphorylation state of the GC receptor, 
where a minor phosphoprotein of 80-kDa GCR phosphorylates 
on serine residues, versus in normal scalp cells the 94-kDa GCR 
phosphorylates exclusively on tyrosine. 
In summary, the above results from scalp biopsies of 15 AA patients 
showed elevated GCR with the ligand binding site unoccupied, along 
with differential phosphorylation of the GCR. Seven patients had very 
depressed TR levels, versus eight with higher TR levels who gave a 
hair-growth response when treated with glucocorticoids. Overall 
conclusions indicate that biochemical measurement ofTR in AA scalp 
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Figure 1. Biochemical pathway for glucocorticoids in alopecia 
areata, where glucocorticoids bind to GCR after the receptor has 
been "activated" by sulfhydryl reduction with TR. Levels ofTR can 
be modulated by calcium/cahnodulin. The GCR is phosphorylated by 
cyclic adenosine monophosphate- dependent protein kinase and cytosol 
kinase mechanisms. In alopecia areata, TR levels are found to be very low, 
hence GCR are elevated and in an unoccupied ligand-binding state. 
biopsies may be a useful marker for predicting glucocorticoid "respon­
sive" hair growth in patients prior to long-term intense glucocorticoid 
treatment. 
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